Table 1_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 2_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 4_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 9_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 8_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 7_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Table 1_Schistosomiasis in Ghana from baseline to now: the impact of fifteen years of interventions.docx حسب Joseph Opare (5437238)

"…Prevalence of schistosomiasis decreased dramatically at first impact assessment, with overall prevalence at 3.5% (95% CI 2.6–4.7) and remained low in recent surveys at 6.8% (95% CI 6.1–7.6), which represents a 67.8% reduction from baseline to current prevalence.…"

Image 11_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Table 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 3_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 6_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 10_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 3_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff حسب James P. Hardwick (20634155)

"…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …"

Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1 حسب Liaozhang Wu (8371008)

"…Mitophagy inhibitor Mdivi-1 reversed the induction of ferroptosis effects of diquat via decreased Fe2+ content and increased Ca2+ level. knockdown of METTL14 reversed the therapeutic effect of Eda on diquat-induced injury. …"